Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Jideytro is a prescription kinase inhibitor containing zidesamtinib. FDA approved it in July 2026 for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who previously received a ROS1 kinase inhibitor. Tablets contain 25 mg or 100 mg.
read more about jideytro ...Zidesamtinib inhibits ROS1 tyrosine kinase, including several ROS1 resistance mutations. Blocking ROS1 signaling reduces growth and survival of susceptible tumor cells. Laboratory studies also found inhibitory activity against ALK and tropomyosin receptor kinases.
Jideytro is used in adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after prior treatment with a ROS1 kinase inhibitor. ROS1-positive status is established before treatment. Current labeling lists no contraindications.
The recommended dose is 100 mg by mouth once daily with or without food until disease progression or unacceptable toxicity. The first dose reduction is 75 mg once daily and the second is 50 mg once daily for treatment-related adverse reactions. Treatment is permanently discontinued when 50 mg once daily is not tolerated.
Serious concerns include central nervous system reactions, QTc interval prolongation, interstitial lung disease or pneumonitis, skeletal fractures, muscle pain with elevated creatine phosphokinase, pancreatic toxicity, and fetal harm. Electrocardiograms, electrolytes, creatine phosphokinase, amylase, and lipase are checked before treatment and monitored as indicated.
Jideytro treats locally advanced or metastatic ROS1-positive non-small cell lung cancer in adults who previously received a ROS1 kinase inhibitor.
The recommended dose is 100 mg once daily with or without food.
Current tablets contain 25 mg or 100 mg of zidesamtinib.
Yes. Jideytro can prolong the QTc interval, so electrocardiograms and electrolytes are monitored during treatment.
FDA Approves Zidesamtinib for ROS1-Positive Non-Small Cell Lung Cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zidesamtinib-ros1-positive-non-small-cell-lung-cancer. Date Accessed October 6, 2026.
JIDEYTRO (Zidesamtinib) Approval Letter. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220185Orig1s000ltr.pdf. Date Accessed October 6, 2026.
JIDEYTRO (Zidesamtinib) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3760e421-b523-4d9b-e063-6394a90ab94b. Date Accessed October 6, 2026.
Zidesamtinib (Jideytro): A New Selective, Brain-Penetrant ROS1 Inhibitor Approved for the Treatment of ROS1-Positive Non-Small Cell Lung Cancer. https://pubmed.ncbi.nlm.nih.gov/42611059/. Date Accessed October 6, 2026.
Zidesamtinib: MedlinePlus Drug Information. https://www.medlineplus.gov/druginfo/meds/a626084.html. Date Accessed October 6, 2026.